Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intensive chemotherapy plus rituximab for patients older that 65 years with newly diagnosed mantle cell lymphoma followed by Zevalin [ibritumomab tiuxetan Y-90] consolidation for complete responders

Trial Profile

Intensive chemotherapy plus rituximab for patients older that 65 years with newly diagnosed mantle cell lymphoma followed by Zevalin [ibritumomab tiuxetan Y-90] consolidation for complete responders

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2006

At a glance

  • Drugs Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Ibritumomab tiuxetan; Methotrexate; Rituximab; Vincristine
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2006 Status change
    • 21 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top